|
|
 |
|
Speeches & Presentations |
|
|
 |
|
|
CEO Fred Hassan's Remarks from the Global Cardiology Summit Sponsored by Schering-Plough in Advance of American Heart Association's Annual Scientific Sessions 2007 - Nov. 2, 2007 |
|
|
|
|
CEO
Fred Hassan's Remarks from the Council of Institutional Investors
Spring 2007 Meeting - March 19, 2007 |
|
|
|
|
CEO Fred Hassan's Remarks from the 3rd Annual Cardiovascular Summit - Nov. 10, 2006
|
|
|
|
|
CEO Fred Hassan's Remarks from The International Federation of Pharmaceutical Manufacturers Meeting - Oct. 12, 2006 |
|
|
|
|
CEO
Fred Hassan's Remarks for Inaugural CEO Lecture Series on Innovation
at Fairleigh Dickinson University - Feb. 23, 2006 |
|
|
|
|
CEO
Fred Hassan's Remarks at the 100th Anniversary Celebration of the
Department of Chemical Engineering Columbia University - Oct. 7, 2005 |
|
|
|
|
CEO
Fred Hassan's Remarks at 15th Anniversary Pharmaceutical Strategic
Alliances Conference - Sept. 26, 2005 |
|
|
|
|
CEO
Fred Hassan's Remarks at the Schering-Plough Sponsored Global Cardiology
Summit in Advance of 2004 American Heart Association's Annual Scientific
Sessions - Nov. 5, 2004 |
|
|
|
|
CEO
Fred Hassan's Remarks at Duke University, The Fuqua School of Business
Distinguished Lecture Series- Sept. 9, 2004 |
|
|
|
|
CEO
Fred Hassan's Remarks at The Pharma, Biotech and Device Colloquium
- June 7, 2004. |
|
|
|
|
CEO
Fred Hassan's Remarks at National Medicare Prescription Drug Congress
- Feb. 26, 2004 |
|
|
|
|
|
The statements made in this speech may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about Schering-Plough's business and prospects. Actual results may differ from these forward-looking statements. Schering-Plough does not assume the obligation to update any forward-looking statements. For further details about risks and uncertainties that may affect forward-looking statements, see Schering-Plough's SEC filings, including Part I, Item 1A. Risk Factors, in the Company's first quarter 2007 10-Q. |
|
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
About Us
